Related content

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

By Galea-Lauri Joanna   Wells James   Darling David   Harrison Phillip   Farzaneh Farzin  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 11, 2004-11 ,pp. : 963-977

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

By                    

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 109-117

Spandidos Publications

Access to resources Recommend Favorite

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

By                  

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 662-668

Spandidos Publications

Access to resources Recommend Favorite

Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer

By Ishikawa Hajime   Imano Motohiro   Shiraishi Osamu   Yasuda Atsushi   Peng Ying-Feng   Shinkai Masayuki   Yasuda Takushi   Imamoto Haruhiko   Shiozaki Hitoshi  

Gastric Cancer, Vol. 17, Iss. 1, 2014-01 ,pp. : 173-180

Springer Publishing Company

Access to resources Recommend Favorite

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

By Brunsvig Paal   Aamdal Steinar   Gjertsen Marianne   Kvalheim Gunnar   Markowski-Grimsrud Carrie   Sve Ingunn   Dyrhaug Marianne   Trachsel Sissel   Møller Mona   Eriksen Jon   Gaudernack Gustav  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 12, 2006-12 ,pp. : 1553-1564

Springer Publishing Company

Access to resources Recommend Favorite